Compare KD & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KD | TMDX |
|---|---|---|
| Founded | 2020 | 1998 |
| Country | United States | United States |
| Employees | 80000 | N/A |
| Industry | EDP Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.6B |
| IPO Year | 2021 | 2019 |
| Metric | KD | TMDX |
|---|---|---|
| Price | $11.64 | $83.24 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 12 |
| Target Price | $14.20 | ★ $97.30 |
| AVG Volume (30 Days) | ★ 3.8M | 629.7K |
| Earning Date | 11-03-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 382.18 |
| EPS | N/A | ★ 0.61 |
| Revenue | ★ $15,092,000,000.00 | $605,494,000.00 |
| Revenue This Year | N/A | $22.50 |
| Revenue Next Year | N/A | $17.93 |
| P/E Ratio | ★ N/A | $128.92 |
| Revenue Growth | 0.23 | ★ 37.13 |
| 52 Week Low | $10.10 | $60.11 |
| 52 Week High | $30.99 | $156.00 |
| Indicator | KD | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 42.13 | 46.88 |
| Support Level | $11.14 | $80.29 |
| Resistance Level | $12.77 | $90.67 |
| Average True Range (ATR) | 0.55 | 3.79 |
| MACD | -0.07 | -0.67 |
| Stochastic Oscillator | 23.86 | 44.10 |
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives. The company's reportable segments consist of the following: Principal Markets which represents its operations in operations in, Canada, France, Germany, India, Italy, Spain, Portugal, and the United Kingdom / Ireland, United States, Japan, and Strategic Markets. It derives maximum revenue from the United States.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.